Sign Up Today and Learn More About iECURE Stock
Invest in or calculate the value of your shares in iECURE or other pre-IPO companies through EquityZen's platform.
iECURE Stock (IEEC)
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
About iECURE Stock
Founded
2012
Headquarters
Philadelphia, PA, US
Industries
Content and Publishing, Messaging and Telecommunications, Advertising
iECURE Press Mentions
Stay in the know about the latest news on iECURE
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
biospace • Mar 26, 2025
In the clinic for March 24, 2025
bioworld • Mar 26, 2025
iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
biospace • Mar 22, 2025
iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
businesswire • Mar 21, 2025
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
biospace • Jan 09, 2025
iECURE Management
Leadership team at iECURE
Vice President, Therapeutic Area Lead, Urea Cycle Disorders
George Diaz
CBO
Alex Monteith
Join now and verify your accreditation status to gain access to:
- iECURE Current Valuation
- iECURE Stock Price
- iECURE Management
- Available deals in iECURE and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- iECURE Cap Table and Funding History by Share Class and Liquidity Preferences
- iECURE Revenue and Financials
- iECURE Highlights
- iECURE Business Model
- iECURE Risk Factors
- iECURE Research Report from SACRA Research
Trading iECURE Stock
How to invest in iECURE stock?
Accredited investors can buy pre-IPO stock in companies like iECURE through EquityZen funds. These investments are made available by existing iECURE shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell iECURE stock?
Shareholders can sell their iECURE stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
